Poster: A Sensitive and Specific Human Primary Stem Cell-Based In Vitro Assay for Predicting The Gastrointestinal Toxicity Risk of Therapeutic Agents

GI Toxicities are the most common drug-induced adverse events in human clinical trials. Unfortunately, they are poorly predicted by rodent models. View our poster presentation from the 2023 SOT meeting authored by James Levi. It describes how a new human-derived cell model provides an efficient and informative screen for drug effects on intestinal cell proliferation. In addition, it screens barrier function toxicities. This model closely resembles natural human physiology.

Abstract 2054: A sensitive and specific human primary stem cell-based in vitro assay for predicting the gastrointestinal toxicity risk of therapeutic agents | Cancer Research | American Association for Cancer Research

Share this article with a friend